Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Structure of the blood-brain barrier
-
1. The blood-brain barrier in Alzheimer’s disease
- Dr. Anika Hartz
-
2. Tanycytes allow a tight BBB in the median eminence
- Prof. Esteban Rodriguez
- Dr. Juan Luis Blazquez
- Dr. Montserrat Guerra
- Nutrient transport
-
3. Blood-brain barrier ion transport
- Prof. Martha O'Donnell
- Peptides and proteins
-
4. Ingestive peptides
- Prof. William Banks
-
5. Blood-brain barrier in health and disease
- Prof. Thomas Davis
- Overcoming the blood-brain barrier obstacle
-
6. Expression vs. function of ABC transporters at the blood-brain barrier
- Prof. Jean-Michel Scherrmann
-
7. The blood-brain barrier and CNS drug development
- Dr. Danica Stanimirovic
- Diseases involving the blood-brain barrier
-
9. Inflammation and immune cell entry to the central nervous system
- Prof. Serge Rivest
-
11. Ischemic blood-brain barrier and Alzheimer's amyloid plaques development
- Prof. Ryszard Pluta
- Latest Developments in the Field
-
12. MRI approaches for neurovascular imaging
- Dr. Rick Dijkhuizen
-
13. Brain-gut interactions in obesity 1
- Prof. Weihong Pan
-
14. Brain-gut interactions in obesity 2
- Prof. Weihong Pan
- Archived Lectures *These may not cover the latest advances in the field
-
15. Neurotrophins and the BBB
- Prof. Weihong Pan
-
16. Vasoactive peptides and the blood-brain barrier
- Prof. Maria Deli
- Prof. Bela Kis
-
17. In vivo systems
- Prof. Quentin Smith
-
18. CNS-drug design
- Prof. Quentin Smith
-
20. Stroke and the BBB
- Prof. Marilyn Cipolla
-
21. Barrier mechanisms in the developing brain: mechanisms and misunderstandings
- Prof. Norman Saunders
-
22. Barrier mechanisms in the developing brain: protection or vulnerability?
- Prof. Norman Saunders
-
23. In vitro models of the blood-brain barrier
- Prof. Pierre-Olivier Couraud
-
24. Glucose transport across the blood-brain barrier
- Prof. Luc Leybaert
-
25. The blood-brain barrier and brain tumors
- Dr. Olaf van Tellingen
-
26. Cellular composition of the blood-brain barrier
- Prof. N. Joan Abbott
-
27. Features of mammalian CNS barrier systems
- Prof. Conrad Johanson
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Neurotrophins and their receptors
- Characteristics of neurotrophins
- Neurotrophin receptors and signals
- Other neurotrophic proteins
- Neurotrophic peptides (naturally occurring)
- Neurotrophic support to the brain and spinal cord
- Blood-brain barrier and blood-spinal cord barrier
- Characteristics of the blood-brain barrier
- NGF 30 minutes after iv injection
- Comparison of neurotrophins kinetic data
- Octanol/PBS partition coefficient
- Capillary depletion 10 minutes after iv
- Saturable transport of NGF
- Saturable transport of NT3
- BDNF 60 minutes after iv
- BDNF entering brain parenchyma
- Saturable transport of BDNF
- Efflux of BDNF
- Classical neurotrophins
- GDNF 30 minutes after iv administration
- Influx of GDNF
- GDNF is relatively stable in circulation
- Influx transport of CNTF
- CNTF degradation assay
- CNTF - conclusion
- LIF
- LIF mainly shows reversible vascular binding
- LIF influx is a saturable process
- Kinetics of LIF influx in the spinal cord
- Examination of LIF influx by in situ brain perfusion
- Blocking antibody, but not CNTF, inhibits LIF influx
- LIF: no efflux transport
- Growth hormone: lack of saturable transport
- In situ brain perfusion data for the growth hormone
- Growth hormone: uptake by brain parenchyma
- Co-injection of insulin and growth hormone
- Insulin does not interfere with IGF1 transport
- Inhibition of IGF-1 transport by insulin
- EGF: example of a neurotrophic peptide
- Recovery of EGF from brain after iv administration
- EGF distribution between brain and blood
- TGFalpha shares the transport system with EGF
- Anti-EGFR Ab showed no effect on EGF influx
- EGFR knock-out mice maintain transport function
- There is no efflux transport system for EGF
- Enhancing CNS delivery of peptides and proteins
- BBB-targeting of BDNF in rats
- Neuroprotective effect of bFGF/OX26-SA conjugate
- Application of a BBB-penetrating form of GDNF
- Effects of IGF-I intranasal administration
- Left forepaw-placing test
- Vestibulomotor function in the beam balance test
- BDNF gene delivery into the CNS
- BDNF levels in transplanted mouse brain cells
- Limitations
- Other means for neuroprotection and regeneration
- Summary
- References
Topics Covered
- Overview of neurotrophins
- CNS physiology and roles in neuroregeneration
- The blood-brain barrier (BBB)
- General strategies to enhance CNS delivery
- Progress on neurotrophin delivery across the BBB
- Limitations and future directions
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Pan, W. (2008, March 1). Neurotrophins and the BBB [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/GGYH7817.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Weihong Pan has no commercial/financial relationships to disclose